Alex Azar, Azar, Big pharma, biotech, China, Clover, Coronavirus Task Force, Eli Lilly, GlaxoSmithKline, GSK, HHS, Indiana, Jun Xiong, Junshi, Palantir, pandemic, patent, Pence, Peter Thiel, Pharma, Shanghai Tanying Investment, Shenzhen Origin Venture Capital, Sichuan Clover, Sir Patrick Vallance, Trump, White House, Wuhan
HHS Secretary Alex Azar was Chair of Trump’s Coronavirus task force until end February, during the most important period to prevent spread. Azar was formerly President of Lilly USA. (Eli) Lilly is based in Indiana. In Dr. Bright’s recent whistleblower complaint, we unsurprisingly read that: “Dr. Bright acted with urgency to begin to address this pandemic but encountered resistance from HHS leadership, including Secretary Azar, who appeared intent on downplaying this catastrophic threat… On February 27, 2020, Secretary Azar testified before the U.S. House of Representatives Ways and Means Committee that “The immediate risk to the public remains low.” He added, “It will look and feel to the American people more like a severe flu season in terms of the interventions and approaches you will see.” https://www.cnn.com/2020/05/05/politics/rick-bright-full-complaint/index.html
Because pharmaceutical patents are so short in duration, pharmaceutical companies need new drugs every couple of decades to prevent or treat old or new diseases. Copyright is too long and patent too short.
VP Pence, who replaced Azar as Coronavirus Chair is from Indiana, as is Seema Verma.
On Monday it was announced that “Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19” May 4, 2020, 9:14 AM EDT https://www.bloomberg.com/press-releases/2020-05-04/junshi-biosciences-junshi-biosciences-and-lilly-to-co-develop-antibody-therapies-for-the-prevention-and-treatment-of-covid-19
“Eli Lilly to partner with Chinese company to find coronavirus treatment” By Shari Rudavsky, Indianapolis Star, May 4, 2020 http://archive.vn/JKIPB
Junshi gets Chinese Rights and Eli Lilly the rest of the world.
The head of Junshi and its largest shareholder is Jun Xiong, who did his undergraduate studies in Wuhan China, and his MBA in Hong Kong.
Remember that Sir Patrick Vallance, who is (or was) the UK’s Chief Scientific Advisor, was President of Research and Development at British Pharmaceutical Company GlaxoSmithKline (GSK) from 2012-17. Vallance suggested that the “herd” of British citizens need to get the coronavirus. GSK partnered with a Chinese pharmaceutical company, more poetically named [Sichuan]”Clover” in an attempt to develop-test a vaccine. https://miningawareness.wordpress.com/2020/03/14/uk-chief-sci-advisor-former-gsk-pharma-exec-wants-to-let-coronavirus-spread-for-herd-immunity/
Why would anyone name a pharmaceutical company Junshi – a ritual suicide? Why would anyone want to take a drug developed by this company? The practice, though Japanese, was known and described by the Chinese: “Junshi (殉死, following the lord in death, sometimes translated as “suicide through fidelity”) refers to the medieval Japanese act of vassals committing seppuku (a voluntary suicide) for the death of their lord. Originally it was only performed when the lord was slain in battle or murdered. The practice is described by Chinese chronicles, describing the Yamato people (the Japanese), going as far back as the 7th century. According to the Weizhi (Chronicle of Wei), a decree in 646 forbade junshi, but it obviously continued to be practiced for centuries afterwards. Under the Tokugawa bakufu, battle and war were almost unknown, and junshi became quite popular with vassals even when their masters died naturally, or in some other way had not met a violent end…” https://en.wikipedia.org/wiki/Junshi
“A woodblock print depicting the wife of Onodera Junai, one of the Forty-seven ronin. She prepares herself to follow her husband into death.” Utagawa Kuniyoshi, Public domain, via wikipedia
“Alex Michael Azar II (/ˈəzɑːr/; born June 17, 1967) is an American attorney, former pharmaceutical lobbyist and executive, and current Presidential cabinet member who serves as the United States Secretary of Health and Human Services. Azar was nominated to his post by President Donald Trump on November 13, 2017, and confirmed by the United States Senate on January 24, 2018. He was also Chairman of the White House Coronavirus Task Force from its inception in January 2020 to February 2020, when he was replaced by Vice President Mike Pence… Effective January 1, 2012, Azar became President of Lilly USA, LLC, the largest division of Eli Lilly and Company, and was responsible for the company’s entire operations in the United States. Prices for drugs rose substantially under Azar’s leadership, including the tripling of the cost of the company’s top-selling insulin drug. Also under Azar’s watch, Eli Lilly was one of three companies accused in a class-action lawsuit of exploiting the drug pricing system to increase profits for insulin. Eli Lilly was also fined in Mexico for colluding on the price of insulin. In connection with the position, Azar served on the board of directors of the Biotechnology Innovation Organization, a pharmaceutical lobby. https://en.wikipedia.org/wiki/Alex_Azar
“In late December 2019, Dr. Bright and other public health officials began taking note when a respiratory virus broke out in Wuhan, China. The CDC issued an official health advisory on January 8, 2020, and by January 11, 2020, the World Health Organization (“WHO”) had issued recommendations for countries to begin taking precautions to try to prevent the spread of COVID-19. Given his decades of expert knowledge on pandemic influenza and emerging infectious diseases, Dr. Bright immediately understood the global reach of this virus. He recognized that lives would depend on the rapid development of effective diagnostics, treatments and vaccines and there was no time to waste. Dr. Bright acted with urgency to begin to address this pandemic but encountered resistance from HHS leadership, including Secretary Azar, who appeared intent on downplaying this catastrophic threat…
On February 27, 2020, Secretary Azar testified before the U.S. House of Representatives Ways and Means Committee that “The immediate risk to the public remains low.” He added, “It will look and feel to the American people more like a severe flu season in terms of the interventions and approaches you will see.”9
A. Dr. Bright encountered opposition from Administration officials as he began pressing for necessary resources to begin vaccine, drug, and diagnostic development.
Unlike Secretary Azar, Dr. Bright and other public health officials were fully aware of the emerging threat of COVID-19 by early January 2020. It was clear to Dr. Bright almost immediately that the virus was highly contagious, spreading rapidly, and could have a high mortality rate. Dr. Bright and his staff recognized the urgent need to obtain genetic sequencing information about the virus and to acquire viruses and clinical specimens from people infected with the virus to share with laboratories and companies. While obtaining both was absolutely critical to being able to develop reliable diagnostic tools and medicines to combat the virus, Dr. Bright initially encountered indifference which then developed into hostility from HHS leadership, including Secretary Azar, as Dr. Bright and his staff raised concerns about the virus and the urgent need to act…” The entire lengthy complaint is here. We have not read it in its entirety. It points to some other pharma conflict of interest connections: https://www.cnn.com/2020/05/05/politics/rick-bright-full-complaint/index.html
Junshi profile: https://www.bloomberg.com/profile/company/1877:HK
The largest shareholder of Junshi is believed to be Jun Xiong with 16% of the shares. He is also top key executive. The second largest owner is Shanghai Tanying Investment Partnership Enterprise (Limited Partnership) (9.8%) and the third is Shenzhen Origin Venture Capital Co., Ltd. (5.6%) http://web.archive.org/web/20200420053623/https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1877/shanghai-junshi-biosciences-shares/news/how-much-of-shanghai-junshi-biosciences-co-ltd-hkg1877-do-insiders-own/
Trump supporter Peter Thiel will make money from the pandemic, too:
Palantir DHHS contracts including recent $17 million one.
Palantir is also now working with the National Health Service (NHS). Thiel was born in Germany and spent some of his formative years in Apartheid South Africa and Namibia, where his father worked as a chemical engineer in the mining industry.
“Palantir Knows Everything About You: Peter Thiel’s data-mining company is using War on Terror tools to track American citizens. The scary thing? Palantir is desperate for new customers. By Peter Waldman, Lizette Chapman, and Jordan Robertson April 19, 2018 https://www.bloomberg.com/features/2018-palantir-peter-thiel/
A lot of people had a lot of incentive to let Covid-19 escape and spread… Patents need to be extended in exchange for lower prices. Without extension then pharmaceutical companies need a new disease every 20 years or so. This could make them tempted to let a disease escape from the multitude of labs that exist all over the world. The Wuhan lab was actually built by the French, who ironically have the highest case fatality rate. It makes no sense that an important product that takes money and talent to create has only a 20 year patent, and anything one writes has a copyright extending beyond death!